SF3B1 and acute myeloid leukemia: These data support work of Pearson et al. [31], who demonstrated that SACLAC treatment led to reduced levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing that increased Mcl-1S levels and contributed to SACLAC-induced apoptosis in AML cells.